NETRAMARK HOLDINGS INC. Aktie

NetraMark received a contract through a partnership with a CRO to analyze Phase 2 study data in the field of neurodegeneration. The company will use its NetraAI platform to identify model-based subgroups and patterns in treatment response to support patient stratification and study design. It is NetraMark's first contract that did not come directly from a biopharmaceutical company; financial details were not disclosed. NetraMark has a market capitalization of USD 893 million and remained unprofitable over the past 12 months with a net loss of USD 3.9 million. » Plus sur de.investing.com

NetraMark has signed a contract with a global biopharma company to analyze patient data from a phase 2 depression study. The firm is using its NetraAI platform to segment multidimensional clinical data, identify patient subpopulations and evaluate treatment-related response patterns. The assignment is intended to yield insights for the sponsor’s future study design; the sponsor was not named and develops therapies for psychiatric and neurological disorders. Financial terms were not disclosed; the stock closed at $27.39 and has gained 36% over the past year. » Plus sur de.investing.com

NetraMark raised $3.11 million in the first, non-brokered tranche of a private placement by issuing 3,110,000 units at $1.00 each; each unit consists of one common share and a half warrant. Whole warrants entitle the holder to acquire one additional common share at $1.35 within two years; the issued securities are subject to a four-month hold period ending May 28, 2026. After the transaction 91,778,520 common shares are outstanding, insiders subscribed for 2,060,000 units, and a second tranche of approximately $390,000 is close to closing; proceeds are to be used for working capital and general corporate purposes. » Plus sur de.investing.com